SUN PHARMACEUTICAL IND L

Sun Pharmaceutical Industries Limited reported its Q1 FY27 earnings, highlighting a sales increase of 10.1% year-over-year, reaching INR 151,836 million. The gross margin improved to 80.5%, attributed to a better product mix. EBITDA rose by 2.7% to INR 44,177 million, with EBITDA margins at 28.9%. The net profit after tax was INR 28,948 million, with an adjusted net profit of INR 30,894 million. The company noted a lower forex gain of INR 1,220 million compared to the previous year. In the U.S. market, sales declined by 9.7% to USD 427 million, primarily due to lower generic sales and increased competition. The India business saw a 16% growth, driven by strong performance in innovative medicines and new product launches. Management also discussed the ongoing acquisition of Organon, which is on track to close by early 2027, and emphasized the importance of their R&D investments, which accounted for 5.4% of sales in the quarter.

The document presented both positive financial growth and challenges in specific markets.